Menu
No results found.
Weekly Share Price & Valuation Overview
Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 387.14M
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 327.97M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 85.39M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 69.58M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD -17.77M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 1.90
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.50
- Shares Outstanding
- 45.44M
- Float Shares
- 20.92M
- Implied Shares Outstanding
- 45.30M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-28.70%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-20.81%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
81.49%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-26.03%
- ROA Return on assets: net income ÷ total assets.
-
-8.67%
- ROE Return on equity: net income ÷ shareholder equity.
-
-24.31%
- Revenue Growth Year-over-year revenue growth.
-
-14.40%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 3.40
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.04
- Total Cash Cash and equivalents.
- USD 62.29M
- Total Debt Short + long-term interest-bearing debt.
- USD 3.12M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- USD -59.17M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -0.18
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD -17.80M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD 1.71M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-20.84%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
2.00%
- Cash Conversion (OpCF/EBITDA)
- 1.00
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.